Antibodies News and Research

RSS

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

Duke receives Gates Foundation grant for HIV vaccine study

The Bill & Melinda Gates Foundation has awarded a new grant to Duke University Medical Center for work developing vaccines that can induce IgA antibodies for preventing HIV-1 infection. This award comes from the Gates' Collaboration for AIDS Vaccine Discovery (CAVD) program.

19 Jul 2012

HCV infections can lead to increased mortality from liver disease or variety of other causes

In a long-term study of people infected with the hepatitis C virus (HCV), researchers found increased deaths from both liver-related and non-liver related diseases in patients with active infections who had not cleared their infection.

19 Jul 2012

CSIRO to produce antibodies for development of new vaccines against rotavirus

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

18 Jul 2012

Vaccination more reliable than observation for bovine herpesvirus

Vaccination halts the circulation of bovine herpesvirus type 1 in dairy herds and should been seen as the best way to eradicate the virus, despite it disappearing without intervention in some herds after long periods, report researchers in the Veterinary Record.

18 Jul 2012

Duke University to receive CHAVI-Immunogen Discovery grant for effective HIV vaccine

A large federal grant awarded to Duke University will fund a highly focused program to discover how to induce the precise immune factors needed for effective vaccines against HIV.

17 Jul 2012

Activating NOTCH and AKT gene may trigger cholangiocarcinoma

A rare type of cancer thought to derive from cells in the bile ducts of the liver may actually develop when one type of liver cell morphs into a totally different type, a process scientists used to consider all but impossible. UCSF researchers triggered this kind of cellular transformation-and caused tumors to form in mice-by activating just two genes.

17 Jul 2012

Thermo Fisher Scientific signs definitive agreement to acquire One Lambda

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that it has signed a definitive agreement to acquire One Lambda, the leader in transplant diagnostics, for $925 million in cash, subject to a post-closing adjustment.

From Thermo Fisher Scientific Inc. 17 Jul 2012

Sandia researchers develop SpinDx medical diagnostic tool

Researchers at Sandia National Laboratories have developed a lab-on-a-disk platform that they believe will be faster, less expensive and more versatile than similar medical diagnostic tools.

14 Jul 2012

Researchers identify potassium channel as an autoantibody target in MS

For the first time, scientists in Germany's multiple sclerosis competence network have been able to identify an antibody that bonds with the potassium channel KIR4.1.

14 Jul 2012

Identification of IL-9 antitumor activity in melanoma

High expression of interleukin -9 in immune cells inhibits growth of melanoma, show study findings suggesting a role for this T-cell cytokine in tumor suppression.

13 Jul 2012

Potassium channel KIR4.1 clue to multiple sclerosis

The potassium channel KIR4.1 is a potential immune target in certain patients with multiple sclerosis, report researchers in TheNew England Journal of Medicine.

12 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

Communication between brain and muscle cells is short-lived without LRP4 protein

Communication between the brain and muscle must be strong for us to eat, breathe or walk. Now scientists have found that a protein known to be on the surface of muscle cells must be present in both tissues to ensure the conversation is robust.

12 Jul 2012

SRI receives NIAID grant to develop HIV vaccine

The Scripps Research Institute has been awarded a grant expected to total more than $77 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID).

12 Jul 2012

TLR1 plays a critical role in protecting the body from food-borne illnesses

A naturally occurring protein called TLR1 plays a critical role in protecting the body from illnesses caused by eating undercooked pork or drinking contaminated water, according to new research from the University of Southern California (USC).

11 Jul 2012

Inspiration receives FDA clinical hold order for IB1001 phase III studies on hemophilia B

Ipsen announced today that its partner Inspiration Biopharmaceuticals Inc. (Inspiration) was notified by the Food and Drug Administration (FDA) that both clinical trials evaluating the safety and efficacy of IB1001, an investigational intravenous recombinant factor IX (rFIX) therapy for the treatment and prevention of bleeding episodes in people with hemophilia B, were placed on clinical hold.

10 Jul 2012

BioView, ScreenCell enter collaboration agreement for imaging of CTC

BioView Ltd. and ScreenCell, a privately-held company, today jointly announced the signing of a commercial collaboration agreement for Bioview's Automated Cell Imaging Systems for imaging of CTC's isolated with ScreenCell's Cyto Kit.

9 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012

Merck, OMT announce new antibody discovery collaboration

Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats to generate antibodies against several targets selected by Merck KGaA.

9 Jul 2012